Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Lauther

Nurse Practitioner, Family Morristown, NJ Nurse Practitioner

NPI 1609221704 CMS profile 11129647

100 Madison Ave, Morristown, NJ 07960

Open in the dashboard

General payments

$20,287

578 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Lauther of Morristown, NJ is reported in the CMS Open Payments database as having received $20,287 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,049 104
2024 General $4,673 131
2023 General $2,282 118
2022 General $6,262 122
2021 General $2,022 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Lauther
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Brittany Lauther were reported at $5,049. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Brittany Lauther Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,022 $124 $35–$379 $132
2022 $6,262 $141 $44–$430 $149
2023 $2,282 $154 $49–$476 $160
2024 $4,673 $165 $51–$504 $164
2025 $5,049 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $9,445 82 payments
  2. AOP Health US, LLC $1,519 2 payments
  3. AstraZeneca Pharmaceuticals LP $1,177 66 payments
  4. Actelion Pharmaceuticals US, Inc. $936 50 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $909 34 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $786 50 payments
  7. Merck Sharp & Dohme Corporation $694 37 payments
  8. Alnylam Pharmaceuticals Inc. $624 38 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $613 36 payments
  10. United Therapeutics Corporation $570 34 payments
  11. Other $3,013 149 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,256 560 payments
  2. Education $6,421 13 payments
  3. Travel and Lodging $610 5 payments
Products named General payments · program years 2021–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $6,408 37 payments
  2. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $1,568 12 payments
  3. Rapiblyk Cardiovascular $1,519 2 payments
  4. Rapiblyk Cardiovascular $1,519 2 payments
  5. UPTRAVI $936 50 payments
  6. LifeVest $909 34 payments
  7. CARDIOMEMS $810 14 payments
  8. VERQUVO $632 28 payments
  9. ONPATTRO $606 37 payments
  10. FARXIGA $553 25 payments
  11. Other $7,769 417 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,068

Median for Nurse Practitioner: 389

Drug cost

$1,922,559

Median for Nurse Practitioner: $21,885

Branded share of claims

33.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 59 $1,559,242
Entresto Sacubitril/Valsartan Brand 114 $150,876
Farxiga Dapagliflozin Propanediol Brand 50 $60,709
Eliquis Apixaban Brand 46 $54,103
Jardiance Empagliflozin Brand 28 $35,713
Lokelma Sodium Zirconium Cyclosilicate Brand 29 $23,717
Xarelto Rivaroxaban Brand 11 $16,037
Vascepa Icosapent Ethyl Brand 21 $8,571
Eplerenone Generic 45 $3,002
Valsartan Generic 38 $2,861

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$32,437

Medicare's payments for the services billed

Medicare patients

123

Average age 76

Services billed

382

46 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 67%
Atrial fibrillation 62%
Diabetes 52%
Arthritis 50%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
$201 — —
VERQUVO
$195 — —
UPTRAVI
$162 — —
FARXIGA
$129 50 —
JARDIANCE
$115 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record